Introduction
============

Neuroendocrine tumors (NETs) are a subtype of neoplasms that can arise in the majority of organs and share a number of common biochemical and pathologic features ([@b1-ol-0-0-11347]). Pulmonary NETs comprise 20--30% of all NETs ([@b2-ol-0-0-11347]), and NETs in the lung can be divided into four subtypes according to their malignancy grade: Typical carcinoids (TCs), atypical carcinoids (ACs), large-cell neuroendocrine carcinomas (LCNECs) and small-cell lung cancers (SCLCs). Of these subtypes, typical and atypical carcinoids are generally termed pulmonary carcinoids and constitute 1--2% of all pulmonary malignancies; however, their incidence has notably increased in recent decades; Petursdottir *et al* ([@b3-ol-0-0-11347]) reported that the incidence of PC increased from 1.9/1,000,000 (1955--1964) to 5.8/1,000,000 (2005--2015) per year in Iceland ([@b4-ol-0-0-11347]). Complete surgical resection is the primary choice of treatment for early-stage lung carcinoids ([@b2-ol-0-0-11347]). However, efficient management strategies for advanced-stage lung carcinoids are limited ([@b2-ol-0-0-11347]). As the development of precision medicine has progressed, molecular targeted therapy has achieved breakthroughs for the treatment of pulmonary carcinoids, including epidermal growth factor receptor (EGFR) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, bevacizumab and tyrosine kinase inhibitors (TKIs) ([@b5-ol-0-0-11347]--[@b7-ol-0-0-11347]). The present study aimed to analyze the clinicopathological characteristics of patients admitted to Tianjin Medical University General Hospital (Tianjin, China) center who underwent surgical resection for pulmonary carcinoids, and gene mutation profiling was performed to explore the underlying molecular mechanisms. In addition, gene mutation information of pulmonary carcinoids was summarized from relevant literature.

Materials and methods
=====================

### Ethical approval

The present study was conducted in accordance with the standards of the Declaration of Helsinki for medical research involving human subjects. All subjects provided written informed consent, and the study protocol was approved by the clinical research ethical review board at Tianjin Medical University General Hospital (Tianjin, China).

### Study design

Patient data were reviewed between January 2006 and December 2016 at Tianjin Medical University General Hospital, and information on 20 patients with lung carcinoid tumors with complete medical records was collected. The clinical features and imaging data from patient records were summarized. All pulmonary carcinoid cases were reviewed according to the World Health Organization criteria (2015) and were staged according to the American Joint Committee on Cancer staging manual (8th edition) criteria ([@b8-ol-0-0-11347],[@b9-ol-0-0-11347]). Carcinoid tumors of the lung were classified as typical carcinoids (TCs) or atypical carcinoids (ACs) based on the following histological differences: The number of mitoses per 10 high-power fields (TC mitotic index, \<2; AC mitotic index, 2--10; SCLC/LCNECs mitotic indices, \>10) ([@b10-ol-0-0-11347]); the presence of necrosis; increased cellularity with disorganization; nuclear pleomorphism; hyperchromatism; and an abnormal nuclear: Cytoplasmic ratio ([@b11-ol-0-0-11347],[@b12-ol-0-0-11347]). In general, macroscopic pulmonary carcinoid tissues appeared as smooth, highly vascular, gray-yellow and notably demarcated masses ([@b1-ol-0-0-11347],[@b9-ol-0-0-11347],[@b13-ol-0-0-11347],[@b14-ol-0-0-11347]). The diagnosis of pulmonary carcinoid can be established by hematoxylin and eosin (HE) staining of a histopathologic section. However, immunohistochemical (IHC) staining is more precise for the diagnosis of pulmonary carcinoids compared with HE; specifically, staining for synaptophysin, chromogranin A and neural cell adhesion molecule (NCAM) can distinguish high-grade NETs (LCNECs and SCLCs) from pulmonary carcinoids ([@b15-ol-0-0-11347]).

Tissue sections (5 µm thick) were prepared from paraffin-embedded tissue blocks using formalin (10% methanol) solution as a fixative. The sections were stained using hematoxylin for 5 min and eosin (HE) for 1 min at room temperature.

### Immunohistochemistry

Stainings for chromogranin A (CgA), synaptophysin (Syn), CD56, thyroid transcription factor 1 (TTF-1), P63, S-100, CK7 and Ki67 were performed by immunohistochemistry for six carcinoid tumors. The tumor tissue samples were fixed in formalin solution (10% methanol) for 48 h at room temperature. The tissues were dehydrated in xylene and graded ethanol series. After being immersed into paraffin wax twice at 60°C and embedded into paraffin blocks, the tumor tissues were cut into 5 µm thick sections. Tissues were deparaffinized in xylene and rehydrated in a graded ethanol series. Microwave pretreatment in 5 mM Tris-HCl (pH 10.0) for 15 min was performed to facilitate heat-induced antigen retrieval. After being rinsed in phosphate buffered saline (PBS), the sections were incubated with primary antibodies against CgA (1:100; Santa Cruz Biotechnology, Inc.; 1:100; cat. no. sc-393941), Syn (Santa Cruz Biotechnology, Inc.; 1:100; cat. no. sc-17750), CD56 (Santa Cruz Biotechnology, Inc.; 1:50; cat. no. sc-7326), TTF-1 (Santa Cruz Biotechnology, Inc.; 1:100; cat. no. sc-53136), P63 (Santa Cruz Biotechnology, Inc.; 1:50; cat. no. sc-25268), S-100 (Santa Cruz Biotechnology, Inc.; 1:100; cat. no. sc-53438), CK7 (Agilent Technologies, Inc.; 1:200; cat. no. M7018) and Ki67 (Santa Cruz Biotechnology, Inc.; 1:100; cat. no. sc-23900) at 4°C overnight. Subsequently, samples were incubated with a secondary antibody mouse IgGκ light chain binding protein (m-IgGκ BP) conjugated to horseradish peroxidase (HRP) (Santa Cruz Biotechnology, Inc.; 1:50; cat. no. sc-516102) for 30 min at room temperature. Diaminobenzidine was used for visualization and followed by hematoxylin for counterstaining at room temperature for 1 min. A light microscope was used to evaluate the staining results at ×100 magnification. All staining slides were evaluated by two researchers to evaluate samples individually.

### Next-generation sequencing

The DNA of 20 lung carcinoid tumors was extracted using QIAamp DNA FFPE tissue kit (Qiagen) according to the manufacturer\'s instructions and evaluated, and via quality control (according to the extent of DNA degradation), six cases were selected for sequencing. Targeted capture sequencing of 56 cancer-associated genes was performed in 6 pulmonary carcinoid tumors (Lung core TM 56 genes; Burning Rock Biotech; [Table SI](#SD1-ol-0-0-11347){ref-type="supplementary-material"}).

The concentration of the DNA samples was measured using the Qubit dsDNA assay (Invitrogen; Thermo Fisher Scientific, Inc.) to ensure that the content of genomic DNA was ≥100 ng. The volume was adjusted to a total of 100 µl using 1X Tris-low EDTA buffer, and the solution was transferred to a Covaris microtube for fragmentation using Covaris M220 (Covaris, Inc.) according to the manufacturer\'s protocol. The DNA was fragmented (average DNA fragment size, 180--220 bp), which was followed by hybridization with the capture probe baits, hybrid selection with magnetic beads and PCR amplification. A high-sensitivity DNA assay was then used to assess the quality and size range. Available indexed samples were sequenced on a NextSeq 500 (Illumina, Inc.) bioanalyzer with pair-end reads.

Raw data from the NextSeq 500 runs were processed with Flexbar software (version 2.7.0) to generate clean FASTQ data, trim adapter sequences and filter and remove poor-quality reads ([@b16-ol-0-0-11347]). The depth for the sequencing in the present study was \~1,000 and Varscan (v. 2.3) was used to call single nucleotide variations and insertions/deletions with MAPQ \>60, base quality \>30 and allele frequency (AF) \>1% ([@b17-ol-0-0-11347]). The variants that comprised \>3 non-duplicated paired reads or \>5 non-duplicated reads were considered as true mutations. Subsequently, clean FASTQ data were aligned to the hg19 (GRCH37) assembly using BWA-sample (Burrows Wheeler Aligner software; version 0.7.12-r1039; <http://sourceforge.net/projects/bio-bwa/files/>), and PCR duplicates were removed using the Mark Duplicates tool in Picard Tools (version 1.124, <http://broadinstitute.github.io/picard/>). All variants were annotated using ANNOVAR (version 20160201) ([@b18-ol-0-0-11347]). Finally, variation frequency (\>0.5%) was used to eliminate erroneous base calling and to generate final mutations, and manual verification was performed using Integrative Genomics Viewer version 2.3.72 ([@b19-ol-0-0-11347]--[@b21-ol-0-0-11347]).

### Statistical analysis

Clinicopathological characteristics of the patients with TC and AC were compared using the unpaired Student\'s t-test (for mean age and tumor diameter), Kruskal-Wallis test \[pathological N and Tumor-Node-Metastasis (TNM) staging\] and χ^2^ test (all other characteristics). A two-tailed P\<0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using SPSS 22.0 software (IBM Corp.).

Results
=======

### Clinical features of the study cohort

The clinicopathological characteristics of 20 patients who underwent surgical resection for pulmonary carcinoid tumors at Tianjin Medical University General Hospital were reviewed and summarized ([Table I](#tI-ol-0-0-11347){ref-type="table"}). Generally, atypical carcinoids are less frequent and the ratio of TCs to ACs is 8--10:1 ([@b4-ol-0-0-11347],[@b22-ol-0-0-11347]); however, of the 20 included cases, 9 were typical carcinoid tumors and 11 were atypical carcinoid tumors. The underlying reasons for this discrepancy are not clear. There was a male predominance in the included population (male:female, 15:5) and the age of patients ranged from 14--71 years with a median age of 48 years. None of the patients with TC tumors presented with lymphatic metastasis, whereas 5/11 (45.45%) patients with AC tumors had lymphatic metastasis, including three cases of N1 and two cases of N2 metastasis. The P-value of the Kruskal-Wallis test was 0.024, which indicated that ACs exhibited a higher malignancy stage. Other clinical characteristics, including the surgical approach, surgical procedure, prescribed adjuvant therapy, tumor sites and TNM stage were considered and compared between TC and AC, and no significant differences were observed ([Table I](#tI-ol-0-0-11347){ref-type="table"}).

Computed tomography images of six patients whose samples were submitted for NGS analysis are presented in [Fig. 1A](#f1-ol-0-0-11347){ref-type="fig"}. The imaging features of pulmonary carcinoids are often similar to those of other lung cancers and have few defining characteristics. The majority of carcinoids appear as round or ovoid peripheral lung nodules with smooth or lobular margins ([@b23-ol-0-0-11347]) and generally exhibit marked enhancement in enhanced CT due to their high vascularity ([@b24-ol-0-0-11347]). Representative images of HE and IHC staining are presented in [Fig. 1B](#f1-ol-0-0-11347){ref-type="fig"}. The specific markers of the six carcinoid tumors were also summarized in [Fig. 1C](#f1-ol-0-0-11347){ref-type="fig"}. The present analysis revealed that ACs exhibited a higher percentage of antigen Ki-67-positive cells and more mitoses per 10 high-power fields; and considering the diagnostic criteria of AC vs. TC, this result was logical and expected.

### Gene mutation analysis of lung carcinoid tumors

The results of NGS are presented in [Table II](#tII-ol-0-0-11347){ref-type="table"} and [Fig. 2](#f2-ol-0-0-11347){ref-type="fig"}. Following the gene mutation profiling of six pulmonary carcinoid tumors, a total of 27 mutations in 21 genes were identified, including *JAK2*, KIT proto-oncogene receptor tyrosine kinase (*KIT*), RB transcriptional coexpressor 1 (*Rb*), neurofibromin 1, TSC complex subunit 1 (*TSC1*), *TSC2*, Erb-B2 receptor tyrosine kinase 4 (*ERBB4*), *NOTCH1*, mitogen-activated protein kinase kinase 1, platelet-derived growth factor receptor α, *ERBB2*, MET proto-oncogene receptor tyrosine kinase (*MET*), *EGFR*, patched 1, insulin-like growth factor 1 receptor (*IGF1R*), kinase insert domain receptor, smoothened frizzled class receptor, *CDK6*, fibroblast growth factor receptor 1 (*FGFR1*), *FGFR2* and *CDK4*. Of these, 11 were proto-oncogenes and 6 were tumor suppressor genes, which indicated that they may participate in tumorigenesis, tumor growth, invasion and metastasis.

The majority of the identified mutations were missense mutations (81.48%), followed by deletion mutations (7.4%) and one case each of nonsense, frameshift and splice donor mutations ([Fig. 2A](#f2-ol-0-0-11347){ref-type="fig"}). All carcinoids had multiple mutated genes, and two patients (33.3%) had multiple mutations in a single gene, including the *TSC1* and *IGF1R* genes ([Fig. 2B](#f2-ol-0-0-11347){ref-type="fig"}). The *KIT, ERBB4, MET* and *IGF1R* genes were mutated in two patients (33.3%). These four genes were considered to be mutated at a high frequency ([Fig. 2A](#f2-ol-0-0-11347){ref-type="fig"}) and were followed (in order of frequency) by 17 other genes that were each mutated in only one case (16.73% of cases) ([Fig. 2A](#f2-ol-0-0-11347){ref-type="fig"}).

Two *KIT* mutations were identified on chromosome 4, but on different exons: Case 1 presented with a missense mutation (G\>A mutation in exon 16; AF 50.4%), whereas case 2 presented with a frameshift mutation (A\>AT mutation in exon 2; AF 2.09%) ([Table II](#tII-ol-0-0-11347){ref-type="table"}). Two *ERBB4* mutations were revealed on chromosome 2. Case 2 harbored a nonsense G\>A mutation in exon 27, whereas case 3 had a missense T\>C mutation in exon 23, resulting in a 35.8% mutation frequency ([Table II](#tII-ol-0-0-11347){ref-type="table"}). The two *MET* mutations were both missense mutations on chromosome 7. Case 3 presented with a C\>T base change in exon 14, whereas case 5 had a G\>A base change in exon 15, yielding a 41.3% mutation frequency ([Table II](#tII-ol-0-0-11347){ref-type="table"}). A total of three *IGF1R* mutations were identified on chromosome 15 in two patients on different exons: Case 4 presented with a G\>A mutation in exon 16, whereas case 6 presented with two C\>T changes in exons 19 and 21.

Discussion
==========

As pulmonary carcinoid is a tumor with a low malignancy rate, resection is often an effective treatment option for early disease; however, for patients with advanced unresectable pulmonary carcinoids, no standardized or authoritative postoperative adjuvant therapy scheme has been established ([@b25-ol-0-0-11347],[@b26-ol-0-0-11347]). In recent years, as the development of precision medicine has progressed, targeted therapy has achieved significant breakthroughs for pulmonary carcinoids, an example of which is mTOR inhibitors ([@b5-ol-0-0-11347]--[@b7-ol-0-0-11347]). However, the progression of therapy in pulmonary carcinoids is still limited due to its low prevalence ([@b26-ol-0-0-11347]), and an in-depth understating of the underlying molecular mechanisms is necessary. Thus, large-scale clinical drug research targeted at pulmonary carcinoids should be proposed as soon as possible. Surgical resection is appropriate for localized diseases; these include locoregional pulmonary carcinoids, cases with limited sites of metastatic disease and local recurrent diseases, such as liver metastases ([@b26-ol-0-0-11347]).

Pulmonary carcinoids are low-grade malignant tumors, and their underlying molecular biological mechanism is yet to be fully elucidated. To understand previous results of pulmonary carcinoid gene sequencing, published literature (PubMed; January 2018) on mutations in pulmonary carcinoids was examined, and available clinical information was summarized in [Table III](#tIII-ol-0-0-11347){ref-type="table"}, comprising 13 studies that referenced 61 cases, including 29 ACs, 31 TCs and 1 indeterminate carcinoid ([@b22-ol-0-0-11347],[@b27-ol-0-0-11347]--[@b38-ol-0-0-11347]). The majority of the articles retrieved utilized first-generation sequencing technology to reveal mutations in single genes or chromosomes, including *PI3K, p53TP53, Rb*, menin 1*, K-ras, c-Met*, ELAV-like RNA-binding protein 4*, 3p14* and *9p*, and no significant associations were observed between specific gene mutations and cancer type, age or sex ([@b22-ol-0-0-11347],[@b27-ol-0-0-11347]--[@b38-ol-0-0-11347]). A total of three studies (including 21 patients) reported NGS data for carcinoids. The mutations of *KIT, ERBB4* and *MET* were also reported in these studies, which supported the findings of the present study ([@b27-ol-0-0-11347]--[@b29-ol-0-0-11347]). Notably, one study that used NGS to investigate carcinoids did not provide the original sequencing data and, consequently, the sequencing results were not summarized in [Table III](#tIII-ol-0-0-11347){ref-type="table"}; however, it was reported in the study that *FGFR1* was highly expressed in carcinoids ([@b39-ol-0-0-11347]). In addition, Rossi *et al* ([@b40-ol-0-0-11347]) also reported that *ERBB4* alteration was detected in carcinoids. Recently, Asiedu *et al* ([@b41-ol-0-0-11347]) used mRNA expression, single nucleotide polymorphism genotyping and a combination of exome and whole-genome sequencing to detect genomic alterations in 31 TC and 11 AC tumors. Compared with the results of Asiedu *et al* ([@b41-ol-0-0-11347]), only a limited number of mutated genes were common to the genes identified using NGS in the present study. The differences between the current study and the previous studies may be attributable to the examination of different targeted gene panels and the different demographic of patients included. In the present study, four genes were revealed to be mutated at a high frequency, including *KIT, ERBB4, MET* and *IGF1R*, which were mutated in 33.3% patients. These genes encode typical tyrosine-protein kinases or receptor tyrosine kinases that are cell surface receptors for multiple signaling pathways and serve an essential role in the regulation of cell survival, proliferation and apoptosis ([@b42-ol-0-0-11347]--[@b45-ol-0-0-11347]). Mutations in these genes are important therapeutic targets of molecular targeted therapeutic drugs, such as the TKIs imatinib and sunitinib ([@b42-ol-0-0-11347]--[@b45-ol-0-0-11347]).

Although certain high-frequency gene mutations were identified, it is difficult to confirm whether the alteration of these genes may initiate and promote pulmonary carcinoid tumors and be effective against targeted therapy. In the future, systematic gene mutation profiling should be performed with a large number of samples to detect potential tumor-promoting genes and to identify potential novel treatment targets for pulmonary carcinoids. This profiling may have important therapeutic implications for the treatment of patients with pulmonary carcinoids.

There are certain limitations the present study; only 6 PCs were collected and this is too few to predict more precise and comprehensive molecular principles of PCs and to conduct survival analysis.

In conclusion, *IGF1R, ERBB4, KIT* and *MET* were identified as frequently mutated genes that may influence the tumorigenesis of pulmonary carcinoid tumors; therefore, targeted therapy against these genes may represent a promising therapeutic strategy for the treatment of this rare disease.
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###### 

Clinicopathological characteristics of patients with pulmonary carcinoid who underwent surgical resection at Tianjin Medical University General Hospital (Tianjin, China).

                                       Total pulmonary carcinoid tumors (n=20)                     
  ------------------------------------ ----------------------------------------- ----------------- -------
  Median age (range), years            48 (28--66)                               49 (14--71)       0.396
  Sex, n (%)                                                                                       0.069
    Male                               5 (55.6)                                  10 (90.9)         
    Female                             4 (44.4)                                  1 (9.1)           
  Smoking history, n (%)                                                                           0.653
    Never                              5 (55.6)                                  5 (45.5)          
    Current/former                     4 (44.4)                                  6 (54.5)          
  History of malignancy, n (%)         3 (33.3)                                  4 (36.4)          0.888
  Median tumor diameter (range), cm    4 (1.5--9.1)                              5.5 (2.1--12.5)   0.252
  Incidence of PET evaluation, n (%)   4 (44.4)                                  3 (27.3)          0.423
  Pathological N stage, n (%)                                                                      0.024
    N0                                 9 (100)                                   6 (54.5)          
    N1                                 0 (0)                                     3 (27.3)          
    N2                                 0 (0)                                     2 (18.2)          
  TNM stage, n (%)                                                                                 0.872
    I                                  4 (44.4)                                  5 (45.5)          
    II                                 2 (22.2)                                  3 (27.3)          
    III                                2 (22.2)                                  2 (18.2)          
    IV                                 1 (11.1)                                  1 (9.1)           
  Tumor site                                                                                       0.946
    Left upper lobe                    1 (11.1)                                  1 (9.1)           
    Left lower lobe                    2 (22.2)                                  3 (27.3)          
    Left hilum                         1 (11.1)                                  2 (18.2)          
    Right upper lobe                   1 (11.1)                                  0 (0)             
    Right middle lobe                  1 (11.1)                                  1 (9.1)           
    Right lower lobe                   2 (22.2)                                  2 (18.2)          
    Right hilum                        1 (11.1)                                  2 (18.2)          
  Surgical approach, n (%)                                                                         0.492
    VATS                               7 (77.8)                                  7 (63.6)          
    Thoracotomy                        2 (22.2)                                  4 (36.4)          
  Procedure, n (%)                                                                                 0.493
    Wedge                              1 (11.1)                                  0 (0)             
    Segmentectomy                      2 (22.2)                                  2 (18.2)          
    Lobectomy                          6 (66.7)                                  9 (81.8)          
  Adjuvant therapy, n (%)                                                                          0.659
    Chemotherapy                       2 (22.2)                                  2 (18.2)          
    Radiotherapy                       1 (11.1)                                  2 (18.2)          

PET, positron emission tomography; VATs, video-assisted thoracoscopic surgery; TNM, tumor-node-metastasis; patients were staged according to the American Joint Committee on Cancer staging manual (8th edition) criteria.

###### 

Gene mutations of patients with pulmonary carcinoids from our cohort.

  Case   Histology   Gene       AA change                                             Mutation type          Frequency (%)
  ------ ----------- ---------- ----------------------------------------------------- ---------------------- ---------------
  1      TC          *JAK2*     K1030R                                                Missense variant       50.60
                     *KIT*      A755T                                                 Missense variant       50.40
                     *RB1*      F198L                                                 Missense variant       9.23
                     *NF1*      S1100T                                                Missense variant       2.24
  2      TC          *TSC2*     R57H                                                  Missense variant       4.33
                     *TSC1*     S1038R                                                Missense variant       3.12
                     *TSC1*     S1039G                                                Missense variant       3.08
                     *ERBB4*    R1155^[a](#tfn3-ol-0-0-11347){ref-type="table-fn"}^   Nonsense variant       2.51
                     *NOTCH1*   E242K                                                 Missense variant       2.26
                     *KIT*      P37S?                                                 Frameshift variant     2.09
  3      TC          *ERBB4*    I944V                                                 Missense variant       35.80
                     *MAP2K1*   D67N                                                  Missense variant       2.89
                     *PDGFRA*   R293H                                                 Missense variant       2.56
                     *ERBB2*    R47H                                                  Missense variant       2.29
                     *MET*      R988C                                                 Missense variant       1.68
                     *EGFR*     NA                                                    Splice donor variant   1.15
  4      TC          *PTCH1*    K251T                                                 Missense variant       49.00
                     *IGF1R*    G8R                                                   Missense variant       2.65
  5      TC          *MET*      V1088M                                                Missense variant       41.30
                     *KDR*      A532V                                                 Missense variant       2.35
  6      AC          *SMO*      P743T                                                 Missense variant       47.50
                     *CDK6*     I159K                                                 Missense variant       7.72
                     *IGF1R*    P1290L                                                Missense variant       4.38
                     *FGFR1*    DDDD163D                                              Deletion variant       4.15
                     *FGFR2*    L192                                                  Deletion variant       3.56
                     *IGF1R*    S1180F                                                Missense variant       2.63
                     *CDK4*     V281E                                                 Missense variant       2.06

TC, typical carcinoid; AC, atypical carcinoid; AA, amino acid

termination codon which signals the end of translation.

###### 

Gene mutation analysis of pulmonary carcinoids from previously published literature.

  Case   Author                  Year   Age   Sex    Type   Mutation                                                Gene/Chromosome   Country    (Refs.)
  ------ ----------------------- ------ ----- ------ ------ ------------------------------------------------------- ----------------- ---------- -----------------------
  1      Hiyama *et al*          1993   77    M      AC     point mutation Cys\>Phe                                 p53               Japan      ([@b38-ol-0-0-11347])
                                                            Deletion mutation                                       Rb                           
  2      Lohmann *et al*         1993   65    F      TC     Neutral mutation Cys\>Tyr                               p53               Germany    ([@b22-ol-0-0-11347])
  3                                     68    M      TC     Missense mutation Glu\>Lys                              p53                          
  4                                     72    F      TC     Missense mutation Val\>Met                              p53                          
  5      Debelenko *et al*       1997   46    NA     TC     Frameshift mutation 1650insC                            MEN1              USA        ([@b37-ol-0-0-11347])
  6                                     56    NA     TC     Alteration of splicing, frameshift mutation 764+3A\>G   MEN1                         
  7                                     63    NA     TC     Frameshift mutation 134del13 (GACGCTGTTCCCG)            MEN1                         
  8                                     49    NA     TC     Frameshift mutation 1699delA and 1702G\>C               MEN1                         
  9      Sagawa *et al*          1998   NA    NA     AC     point mutation                                          K-ras             USA        ([@b36-ol-0-0-11347])
  10     Couce *et al*                  52    F      AC     K-ras c12 Gly\>Ser missense mutation                    K-ras             USA        ([@b35-ol-0-0-11347])
  11                                    39    F      AC     K-ras c12 Gly\>Asp missense mutation                    K-ras                        
  12                                    61    F      AC     Exon 8 c298 Glu\>Stop missense mutation                 p53                          
  13     Sugio *et al*           2003   NA    NA     AC     Loss of heterozygosity in 3p14                          3p14              Japan      ([@b34-ol-0-0-11347])
  14                                    NA    NA     AC     Loss of heterozygosity in 9p                            9p                           
  15     Snabboon *et al*        2005   68    F      TC     Deletion mutation at exon 10 (1793delG)                 MEN1              Thailand   ([@b33-ol-0-0-11347])
  16     D\'Alessandro *et al*   2010   29    F      TC     Exon 5 c.733-16C\>T                                     ELAVL4            Italy      ([@b32-ol-0-0-11347])
  17                                    50    M      TC     Exon 5 c.666A\>T                                        ELAVL4                       
                                                            Exon 5 c.712C\>T                                        ELAVL4                       
  18                                    70    F      TC     Somatic mutation Exon 4 c.424delA                       ELAVL4                       
                                                            Exon 5 c.559G\>A                                        ELAVL4                       
  19                                    47    M      AC     Exon 4 c.387C\>T                                        ELAVL4                       
                                                            Single nucleotide polymorphism                          ELAVL4                       
                                                            Exon 5 c.687T\>C                                                                     
                                                            c.1367+56C\>T 3′UTR                                     ELAVL5                       
  20                                    54    M      AC     Somatic mutation Exon 5                                 ELAVL4                       
                                                            c.655C\>T                                                                            
                                                            Exon 5 c.704G\>A                                        ELAVL4                       
  21     Capodanno *et al*       2012   NA    NA     TC     Missense mutation c.1576 A\>G                           PI3K              Italy      ([@b31-ol-0-0-11347])
  22                                    NA    NA     TC     Missense mutation c.1639 G\>A                           PI3K                         
  23                                    NA    NA     TC     Missense mutation c.1639 G\>A                           PI3K                         
  24                                    NA    NA     TC     Missense mutation c.1639 G\>A                           PI3K                         
  25                                    NA    NA     AC     Missense mutation c.1639 G\>A                           PI3K                         
  26                                    NA    NA     TC     Missense mutation c.2993 T\>C                           PI3K                         
  27                                    NA    NA     AC     Missense mutation c.3007 T\>C                           PI3K                         
  28                                    NA    NA     AC     Missense mutation c.3017 T\>C                           PI3K                         
  29                                    NA    NA     AC     Missense mutation c.3022 T\>C                           PI3K                         
  30                                    NA    NA     TC     Missense mutation c.3034 G\>A                           PI3K                         
  31                                    NA    NA     AC     Missense mutation c.3041 A\>G                           PI3K                         
  32                                    NA    NA     AC     Missense mutation c.3050 A\>T                           PI3K                         
  33                                    NA    NA     AC     Missense mutation c.3062 A\>G                           PI3K                         
  34                                    NA    NA     TC     Missense mutation c.3061 T\>A                           PI3K                         
  35                                    NA    NA     AC     Missense mutation c.3068 G\>A                           PI3K                         
  36                                    NA    NA     TC     Missense mutation c.3133 G\>A                           PI3K                         
  37                                    NA    NA     TC     Missense mutation c.3145 G\>A                           PI3K                         
  38                                    NA    NA     TC     Missense mutation c.3145 G\>A                           PI3K                         
  39                                    NA    NA     AC     Missense mutation c.3155 C\>T                           PI3K                         
  40     Voortman *et al*        2013   NA    NA     TC     Missense mutation Exon 14 T1010I mutation               c-Met             USA        ([@b30-ol-0-0-11347])
  41     Armengol *et al*        2015   69    Male   TC     Missense mutation c.1796C\>T                            BRAF              Finland    ([@b29-ol-0-0-11347])
                                                            Missense mutation c.1496G\>A                            SMAD4                        
                                                            Missense mutation c.3074C\>T                            SMAD4                        
                                                            Missense mutation c.38G\>A                              KRAS                         
  42     Vollbrecht *et al*      2015   NA    NA     AC     Missense mutation c.311T\>A                             EGFR              Germany    ([@b28-ol-0-0-11347])
                                                            Missense mutation c.311T\>A                             EGFR                         
                                                            Insertion mutation c.2516_2517insC                      GNAS                         
                                                            Deletion mutation c.1912delA                            KIT                          
                                                            Missense mutation c.1015C\>T                            PTEN                         
  43                                    NA    NA     AC     Deletion and insertion mutation                         KDR                          
                                                            c.1416_1417delinsTA                                                                  
  44                                    NA    NA     AC     Missense mutation c.2744C\>A                            ERBB4                        
  45                                    NA    NA     AC     Missense mutation c.3788G\>A                            APC                          
                                                            Insertion mutation c.855_856insG                        FGFR1                        
                                                            Insertion mutation c.3730_3731insC                      MET                          
  46                                    NA    NA     AC     Deletion and insertion mutation                         RET                          
                                                            c.2712_2713delinsGG                                                                  
  47                                    NA    NA     AC     Deletion and insertion mutation                         ERBB2                        
                                                            c.2354_2355delinsGG                                                                  
  48                                    NA    NA     AC     Missense mutation c.3367C\>T                            APC                          
                                                            Missense mutation c.112G\>A                             KRAS                         
  49                                    NA    NA     AC     Deletion mutation c.862delG                             HNF1A                        
  50                                    NA    NA     AC     Missense mutation c.2602C\>T                            ERBB2                        
                                                            Missense mutation c.1100T\>G                            SMO                          
  51                                    NA    NA     AC     Deletion and insertion mutation                         KIT                          
                                                            c.1637_1638delinsGG                                                                  
                                                            Missense mutation c.274C\>T                             PI3K                         
                                                            Missense mutation c.167C\>T                             SMARCB1                      
  52                                    NA    NA     AC     Insertion mutation c.3730_3731insC                      MET                          
  53                                    NA    NA     TC     Deletion and insertion mutation                         RET                          
                                                            c.2711_2713delinsTGG                                                                 
  54                                    NA    NA     TC     Missense mutation c.3386T\>C                            APC                          
  55                                    NA    NA     TC     Missense mutation c.2624C\>T                            ERBB2                        
  56                                    NA    NA     TC     Deletion and insertion mutation                         ERBB2                        
                                                            c.2354_2355delinsGG                                                                  
  57                                    NA    NA     TC     Missense mutation c.2531G\>A                            GNAS                         
  58                                    NA    NA     TC     Missense mutation c.2318A\>C                            EGFR                         
                                                            Missense mutation c.274T\>A                             IDH1                         
                                                            Missense mutation c.267A\>C                             IDH1                         
  59                                    NA    NA     TC     Deletion and insertion mutation                         PDGFRA                       
                                                            c.2471_2472delinsCT                                                                  
  60                                    NA    NA     TC     Missense mutation c.920C\>T                             ABL1                         
                                                            Missense mutation c.505C\>T                             SMAD4                        
  61     Lou *et al*             2017   23    Male   NA     NA                                                      PI3K              China      ([@b27-ol-0-0-11347])

NA, not available; *Rb*, RB transcriptional corepressor 1; *MEN1*, menin 1; *ELAV4*, ELAV-like RNA-binding protein 4; PI3K, phosphatidylinositol 3-kinase, putative; NA, not applicable.

[^1]: Contributed equally
